More Videos
SPECIAL REPORT
MOST SHARED
- A Public Hearing That Isn't Public
- Warren Buffett and Bill Gates Share Their 'Optimism' With Eager Columbia Business Students
- Meet The Leaders of the New Retail Revolution
- Cities With the Most Home Price Reductions
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- Despite Rhetoric, Obama Has Limited Options To Boost Jobs
- Housing Recovery 'Still In Uncharted Territory': HUD Secretary
- Disney CFO and Parks Chief to Swap Roles
- For Video Game Makers, Stakes Are High for The Holidays
- Intel's Andy Bryant Offers An Explanation
- US 'Actively Working' on Weaker Dollar: Fund Manager
- Options Boil on Biotech Buyout Rumors
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Activision Blizzard's "Modern Warfare 2" Sales Break Records
- 5-Star Manager's 5 Stocks for Changing Markets
- What's The Forecast from Retailers? Proceed With Caution
- Disney's CFO-Theme Park Chairman Executive Swap
- Road Rage Rants
- AIG, Symbol of Crisis, Watches Its Stock Zoom Back
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- Despite Rhetoric, Obama Has Few Options to Boost Jobs
- Cities With the Most Home Price Reductions
- US Debating What to Do With Billions of TARP Money Left
- Alleged Florida Ponzi Scheme Could Top $1 Billion
- Forecast From Retailers: Proceed With Caution
- Nordstrom Earnings Miss Forecasts; Shares Take Hit
- Housing Recovery 'In Uncharted Territory': HUD Chief
RSS FEED
Pharma's Market
Text Size 
 |
Sidney Taurel |
Meantime, Joe Kernen had just walked off the set after wrapping up "Squawk Box" and as he sauntered by, he shouted, "Hey, Huckman! Did you see Sidney Taurel's op-ed piece in 'The Journal'? He mentions you by name!" Okay, drop everything. I quickly opened the front section to the op-ed page and scanned the piece headlined, "The Media on Drugs" (don't like that turn of phrase, by the way) by none other than the Chairman and CEO of Eli Lilly [LLY
Loading...
()
] , Sidney Taurel. Here's the link. Can't find my name. Turns out Kernen, as is his way, was referring to the Huckman reference as a 'read between the lines' kind of thing. Taurel doesn't name any names.
Taurel is complaining about the media coverage of recent news surrounding his company's experimental bloodthinner which sent his stock into a swoon. First, a report--which CNBC did not break, but did cover--about LLY halting enrollment in two small clinical trials of the drug. And second, about the subsequent embargoed results of a large study of LLY's prasugrel versus Plavix from Bristol-Myers Squibb [BMY
Loading...
()
] and Sanofi-Aventis [SNY
Loading...
()
] . Taurel admonishes the news media to not "trade in leaks and rumors where scientific data are concerned. Wait for real numbers, and take the time to explain statistics and benefit risk analysis, which cannot be conveyed in sound bites alone." And throughout the piece he refers to the "media beast" which he accurately portrays as needing to be fed almost 24/7.
I think Taurel is shooting the messenger. Lilly had to know that the original story about the halted clinical trials was going to break. And, if so, it had a golden opportunity to try to get out in front of it and do some spin control. For example, offer up high-level executives to reporters immediately. Put out a more detailed statement than the one it released. The company might argue that its hands were tied because of the pending embargo on the larger clinical trial results which were soon due to be presented at the American Heart Association meeting and published in "The New England Journal of Medicine."
But I suspect that given the extraordinary circumstances--the news of the two smaller studies being halted and the steep $6 billion decline in LLY's market value because of it--that the company might have been able to convince AHA and/or NEJM to loosen up a little and let its officials discuss at least some of the results in an open forum, pre-embargo.
I could be wrong, though, as scientific organizations and medical journals are extremely protective of their material because they want the big media bang that occurs when an embargo lifts, especially on a huge, highly-anticipated clinical trial like this one.
If Lilly doesn't cancel, I will be doing a live interview with Mr. Taurel on "Squawk Box" ahead of his company's analyst meeting in New York next week. He and I have enjoyed a good working relationship. He's almost always been accessible and is one of the few big pharma CEOs who doesn't shy away from the camera and is adept at fielding rapid-fire questions on a variety of topics "live" and on the fly. So, I'm looking forward to what I hope will be an enlightening discussion about whether it's the media or Eli Lilly who's "on drugs".
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes